H.I.G. WhiteHorse Europe Finances Stordata
26.3.2024 16:30:00 EET | Business Wire | Press release
H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a financing package for Stordata (the “Company”).
Founded in 1988, and headquartered in Versailles, France, Stordata has established itself as a reference partner for the digital transformation of mid-size and large companies, with around 500 clients. An expert in architecture, administration, and maintenance of security and data management systems, particularly in the cloud, the Company provides critical continuous access services to its clients. The services allow clients to leverage their data in a complex and constantly evolving IT environment. The Company has experienced sustained growth in recent years and is developing additional service offerings around cybersecurity and cloud services.
Stordata is embarking on a new chapter in its development through the acquisition of a majority stake by funds advised by Elyan Partners (“Elyan”), a member of the Edmond de Rothschild Private Equity partnership from the founders and executives of the Company, who are reinvesting in the Company.
H.I.G. WhiteHorse Europe has arranged a bespoke financing package, which will be used to finance the acquisition and provide additional capital to support the Company’s expansion, especially through an active buy-and-build strategy.
H.I.G. WhiteHorse Europe, through some of its affiliates, acted as the sole arranger, while Caisse d’Epargne et de Prévoyance Hauts de France participated in the financing alongside H.I.G. WhiteHorse.
Marc Michel, Co-Founder, and Olivier Teichman, CEO of Stordata, said: “Stordata’s success is built on the technical expertise of our employees, the quality of service delivered to our clients, and the trust placed in us by our technology partners. We are so grateful for their continued support. We are also excited by our new partnership with Elyan and appreciative of the confidence we received from H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France. We believe Stordata is poised for a robust growth phase.”
Jeremie Melin and Vincent Manes, Partners at Elyan said: “We have been impressed by what Stordata has built over the past years. We are convinced that it can be the foundation of an ambitious growth in France and in Europe, to offer even more value and expertise to Stordata’s clients, particularly in cybersecurity and in the cloud. With H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France, we believe we have the right like-minded partners who understand the business and share common values and vision.”
Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Stordata has embarked on a remarkable growth journey in recent years, leveraging its expertise in security and data management, further reinforcing its position in the French digital transformation sector. We are excited to partner with a very experienced investor in Elyan and to contribute to the future success of the Company via a tailor-made financing.”
Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We are delighted to support Stordata and Elyan. We have been impressed by Stordata’s very high level of expertise and by the quality of its management team. Stordata's strong market reputation and significant market share have firmly established the company as the market leader among mid- and large-size clients.”
About Stordata
Stordata is an independent expert in data and virtualization, combining consulting, transformation management, administration, and maintenance of data security and management systems. Its cloud offering (StorCloud) is ISO27001 and HDS (Hébergeurs de Données de Santé - Health Data Hosts) certified.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $60 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
About Elyan Partners & ERES IV
Elyan Partners SAS is a financial investment advisor and partner of Edmond de Rothschild Private Equity. Elyan is the exclusive advisor to the ERES funds and an advisor to the Privilege funds of the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America.
Edmond de Rothschild Private Equity is the trade name of the Edmond de Rothschild Group’s private equity entities and has over CHF 3.6 billion of assets under management. Founded in 1953, the Group had nearly CHF 158 billion in assets under management as of 31 December 2022, 2,500 employees, and 30 offices worldwide.
*Based on total capital raised by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326501486/en/
Contact information
Pascal Meysson
Head of H.I.G. WhiteHorse Europe
pmeysson@hig.com
Charles Bourgeois
Managing Director
cbourgeois@hig.com
H.I.G. WhiteHorse Europe
P +44 (0) 207 318 5700
hig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
